^
Association details:
| Biomarker: | PD-L1 expression + CTLA4 expression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | GI-101 (PD-L1 inhibitor, CTLA4 inhibitor, CD122 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1826 - Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target
Published date:
03/10/2021
Excerpt:
To mimic the standard care (SOC) in clinic, TC1 lung cancer model was involved in evaluating the efficacy of both 1st line and maintenance therapy of GI-101...GI-101 elicits improved restoration of immune functions in human PBMCs co-cultured setting with PD-L1/CTLA-4 co-expressed tumor cells.
